AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients with Active, R/R AML in the Phase 3 SIERRA Trial
Clinical Lymphoma Myeloma and Leukemia（2024）
关键词
AML,relapsed/refractory,131I-apamistamab,allogeneic stem cell transplant,radioimmunoconjugate,phase 3
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要